Literature DB >> 3000026

Clinical significance of respiratory infection caused by Branhamella catarrhalis with special reference to beta-lactamase producing strains.

T Nagatake.   

Abstract

I found the recent increase during the past eight years of the incidence of respiratory infections caused by Branhamella catarrhalis. Namely, I experienced 74 cases (93 episodes) of the respiratory infections; 5 pneumonia, 14 acute bronchitis, 1 lung abscess, 36 chronic bronchitis, 7 chronic bronchiolitis, 21 bronchiectasis and 9 chronic pulmonary emphysema with infection. In 65 of 93 infectious episodes, Branhamella catarrhalis was isolated as a pure culture and in 28 episodes it was associated with other organisms, 13 Haemophilus influenzae etc. In all the cases, a positive correlation was found between beneficial clinical results and disappearance of the organism from the sputum. Minimum inhibitory concentrations of the representative beta-lactam and other antibiotics against 104 strains were determined. All of these strains were obtained during last four years from 1980 to 1983 from the purulent sputa as the main pathogen. Annually, this organism has significantly acquired resistance to beta-lactams. By 1983, 74% of Branhamella catarrhalis isolated from the purulent sputa became a beta-lactamase producers. And the failure cases of Branhamella catarrhalis infections treated with beta-lactams have increased during the last two years. These results have clearly showed also the importance of Branhamella catarrhalis as the common pathogen for respiratory organ.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3000026     DOI: 10.1620/tjem.147.1

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

1.  The macrophage response to bacteria. Modulation of macrophage functional activity by peptidoglycan from Moraxella (Branhamella) catarrhalis.

Authors:  R Keller; J E Gustafson; R Keist
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 2.  Branhamella catarrhalis: an organism gaining respect as a pathogen.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

3.  A monoclonal antibody reactive with a common epitope of Moraxella (Branhamella) catarrhalis lipopolysaccharides.

Authors:  K Oishi; H Tanaka; F Sonoda; S Borann; K Ahmed; Y Utsunomiya; K Watanabe; T Nagatake; M Vaneechoutte; G Verschraegen; K Matsumoto
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

Review 4.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

5.  Serum antibody response to proteins of Moraxella (Branhamella) catarrhalis in patients with lower respiratory tract infection.

Authors:  J J Christensen; J Renneberg; B Bruun; A Forsgren
Journal:  Clin Diagn Lab Immunol       Date:  1995-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.